130 related articles for article (PubMed ID: 23257842)
1. Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).
Braester A; Akria L; Suriu C; Sonkin V
Acta Haematol; 2013; 129(3):185-6. PubMed ID: 23257842
[No Abstract] [Full Text] [Related]
2. Aspergillus fumigatus osteomyelitis in a patient receiving alemtuzumab for B-cell chronic lymphocytic leukaemia.
Karia S; Jeyapalan K; Kennedy B
Br J Haematol; 2011 Apr; 153(2):147. PubMed ID: 21332707
[No Abstract] [Full Text] [Related]
3. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Reda G; Maura F; Gritti G; Gregorini A; Binda F; Guidotti F; Piciocchi A; Visco C; Rodeghiero F; Cortelezzi A
Am J Hematol; 2012 Sep; 87(9):936-7. PubMed ID: 22718434
[TBL] [Abstract][Full Text] [Related]
4. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia.
Henn A; Mellon G; Benoît H; Roos-Weil D; Jauréguiberry S; Mordant P; Fekkar A; Caumes E
Scand J Infect Dis; 2014 Mar; 46(3):231-4. PubMed ID: 24450842
[TBL] [Abstract][Full Text] [Related]
5. Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab.
Niscola P; Ragusa D; Scaramucci L; Giovannini M; Piccioni D; Tendas A; Perrotti A; de Fabritiis P; Del Poeta G
Ann Hematol; 2014 May; 93(5):863-5. PubMed ID: 23949377
[No Abstract] [Full Text] [Related]
6. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
[No Abstract] [Full Text] [Related]
7. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
[No Abstract] [Full Text] [Related]
8. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
9. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
Gibbs SD; Westerman DA; McCormack C; Seymour JF; Miles Prince H
Br J Haematol; 2005 Jul; 130(1):87-91. PubMed ID: 15982349
[TBL] [Abstract][Full Text] [Related]
10. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.
Cortelezzi A; Gritti G; Laurenti L; Cuneo A; Ciolli S; Di Renzo N; Musto P; Mauro FR; Cascavilla N; Falchi L; Zallio F; Callea V; Maura F; Martinelli S; Piciocchi A; Reda G; Foà R;
Br J Haematol; 2012 Feb; 156(4):481-9. PubMed ID: 22150204
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
12. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.
Pitini V; Cascio A; Arrigo C; Altavilla G
Br J Haematol; 2012 Jan; 156(1):1. PubMed ID: 21790529
[No Abstract] [Full Text] [Related]
13. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA).
Kroft SH; Tallman MS; Shaw JM; Thangavelu M; Peterson LC
Leukemia; 1997 Jan; 11(1):170. PubMed ID: 9001435
[No Abstract] [Full Text] [Related]
14. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
15. Pact with the devil: alemtuzumab therapy, immune suppression and infectious complications in chronic lymphocytic leukemia.
Antohe I; Dascalescu A; Burcoveanu C; Ghiorghiu D; Dascalu A; Danaila C
Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):92-5. PubMed ID: 24741782
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
Traynor K
Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
[No Abstract] [Full Text] [Related]
17. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Demko S; Summers J; Keegan P; Pazdur R
Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
19. Paraneoplastic pemphigus associated with chronic lymphocytic leukaemia: treatment with alemtuzumab.
Ekbäck M; Uggla B
Leuk Res; 2012 Aug; 36(8):e190-1. PubMed ID: 22579369
[No Abstract] [Full Text] [Related]
20. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
